All Type of News
MFDS’s schematic design study to be completed next month
The schematic design study which include reorganization of emergency contraceptives is going to be finalized within next month. How much influence the result of the study, which will draw base data of the reorganizati...
Hanmi Pharm, history maker, to record most pharmaceutical manufacturing outputIt was known among the top 20 domestic pharmaceutical companies Hanmi Pharm recorded the highest pharmaceutical manufacturing output last year.
According to the analysis result...
|
Sanofi chose Hanmi against threat of Lantus patent expirationThe reason why Sanofi established a technology transfer contract worth of KRW 5 trillion with Hanmi Pharm is analyzed as the company considered the patent expiration of ‘Lantus,...
|
USTR requested to reconsider Original Medicine Cost Collection Act
The U.S. has expressed a sensitive response to the amendment to the National Health Insurance Act for the Patent-Linkage System’s Medicine Cost Collection on Original Companies, which has been docked in the National A...
Remarkable ‘clinical studies’ of domestic pharmaceutical companies focusing on future-oriented treatments
Domestic companies have always had desire towards new drugs. However, the problem is it takes so much more time and money to invest in new drugs than generics.
Recently, however, domestic pharmaceutical companies hav...
Will domestic entry of Avastin make Roche worried?
Domestic clinical trials of biosimilars have been actively conducted towards ‘Avastin(generic name: bevacizumab),’ a VEGF(Vascular endothelial growth factor) targeted anticancer drug.
On the 5th, Quintiles Transnatio...
Hanmi established license contract of diabetes treatments with Sanofi for EUR 400 millionHanmi Pharm announced on the 5th that Sanofi established a license contract for the Quantum Project, a portfolio of long-acting diabetes new drugs, which has been developed by H...
|
“The belief of Hanmi Pharm President Sung-gi Lim to develop new drugs has been glowing”The belief of President Sung-gi Lim of Hanmi Pharm, which has focused on R&D investment for the past 15 years, has been glowing in the global pharmaceutical market.
On the 5th,...
|
‘Suglat’ landed in large hospitals after ‘Forxiga’
It was observed ‘Suglat,’ a SGLT-2 inhibitor recognize as a new diabetes drug, has been settled in large hospitals, followed by the same type drug, ‘Forxiga.’
According to the observation of Medipana News on the 6th,...
Beginning of prescription competition between Tresiba and Toujeo
The active competition among next-generation insulin has begun.
According to the industry concerned on the 28th, after Novo Nordisk registered the health insurance benefit of ‘Tresiba(insulin degludec),’ a basal insu...
